Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAGE 324

Next Previous
Drug Profile

SAGE 324

Alternative Names: BIIB-124; SAGE-324

Latest Information Update: 20 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SAGE Therapeutics
  • Class Antiepileptic drugs; Antiparkinsonians; Small molecules
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy
  • No development reported Parkinson's disease
  • Discontinued Essential tremor

Most Recent Events

  • 20 Feb 2025 SAGE 324 is still in phase I trials for Epilepsy in the US (Sage Therapeutics pipeline, February 2025)
  • 11 Feb 2025 Biogen and Sage Therapeutics terminates the collaboration to develop and commercialize SAGE 324 for Essential tremors, Epilepsy and Parkinson's disease (SAGE Therapeutics pipeline, February 2025)
  • 11 Feb 2025 Sage Therapeutics plans a phase II trial in Epilepsy (Sage Therapeutics pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top